The trial achieved both its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and exceptional improvements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in those wit